84547-59-1

Usage

InChI:InChI=1/C5H5ClN2O/c1-8-4(5(6)9)2-3-7-8/h2-3H,1H3

Upstream product

• 16034-46-1 1-methyl-1H-pyrazole-5-carboxylic acid 
• 7719-09-7 thionyl chloride 

Downstream Products

• 84547-61-5 (1-methyl-1H-pyrazol-5-yl)methanol 
• 131293-07-7 1-(1-methyl-1H-pyrazol-5-yl)-3-phenylprop-2-yn-1-one 
• 132668-86-1 trans, trans-1,4-bis<2-(1-methylpyrazol-5-yl)vinyl>benzene 
• 84547-71-7 1-methyl-5-(p-nitrostyryl)pyrazole 
• 920002-93-3 2-Methyl-2H-pyrazole-3-carboxylic acid [3-(2-oxo-2,3-dihydro-1H-indole-6-carbonyl)-phenyl]-amide 
• 1005784-61-1 N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1-methyl-1H-pyrazole-5-carboxamide 
• 137890-05-2 1-(1-methyl-1H-pyrazol-5-yl)ethan-1-one 
• 1318757-58-2 N-{4-[(1S)-1-hydroxyethyl]-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 
• 1318757-57-1 (R)-N-{4-(1-hydroxyethyl)-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 
• 1318754-62-9 N-{4-(methoxymethyl)-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 
• 1318754-63-0 N-{4-(1-hydroxy-1-methylethyl)-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 
• 1318757-59-3 N-(2-(hydroxy(3-(trifluoromethyl)phenyl)methyl)-4-(2-hydroxypropan-2-yl)thiazol-5-yl)-1-methyl-1H-pyrazole-5-carboxamide 
• 1318754-64-1 1-methyl-N-{4-(1-methylethyl)-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1H-pyrazole-5-carboxamide 
• 1318754-66-3 N-{4-ethenyl-2-[3-(trifluoromethyl)benzyl]-1,3-thiazol-5-yl}-1-methyl-1H-pyrazole-5-carboxamide 

Relevant academic research and scientific papers

FUSED AZOLE HETEROCYCLES AS AHR ANTAGONISTS

The present disclosure relates to thiazolo-pyridine, oxazolo-pyridine, pyrrolo-pyridine, pyrrolo-pyrazine and pyrrolo-pyrimidine compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing

FUSED IMIDAZOLE DERIVATIVES AS AHR ANTAGONISTS

The present disclosure relates to compounds of formulae (I) - (VI) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling.

Vinylogous Elimination/C-H Functionalization/Allylation Cascade Reaction of Allenoate Adducts: Synthesis of Ring-Fused Dihydropyridinones

A palladium-catalyzed cascade reaction of β′-allenoate adducts with aryl/heteroaryl carboxamides through a vinylogous elimination/C-H functionalization/intramolecular allylation reaction sequence has been developed with high Z stereoselectivity. Various ring-fused dihydropyridinones bearing an α,β-unsaturated ester substituent are obtained. It is the first example of application of the allenoate adducts to C-H functionalization annulations as practical precursors of hard-to-get functionalized electron-deficient 1,3-butadienes. Using air as the terminal oxidant also shows a great advantage in environmental friendliness.

NAPHTHYRIDINES AS INHIBITORS OF HPK1

Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain. Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chemical matter that is efficacious in preclinical models of neuropathic and inflammatory pain. (Chemical Presented).

Pyrimidinone Derivatives as Antimalarial Agents

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

Cu(II)-mediated C-H amidation and amination of arenes: Exceptional compatibility with heterocycles

A Cu(OAc)2-mediated C-H amidation and amination of arenes and heteroarenes has been developed using a readily removable directing group. A wide range of sulfonamides, amides, and anilines function as amine donors in this reaction. Heterocycles present in both reactants are tolerated, making this a broadly applicable method for the synthesis of a family of inhibitors including 2-benzamidobenzoic acids and N-phenylaminobenzoates.

Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics

For the purpose of discovering novel type-II inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2) kinase, we designed and synthesized 5,6-fused heterocyclic compounds bearing a anilide group. A co-crystal structure analysis of imidazo[1,2-b]pyridazine derivative 2 with VEGFR2 revealed that the N1-nitrogen of imidazo[1,2-b]pyridazine core interacts with the backbone NH group of Cys919. To retain this essential interaction, we designed a series of imidazo[1,2-a]pyridine, [1,2,4]triazolo[1,5-a]pyridine, thiazolo[5,4-b]pyridine, and 1,3-benzothiazole derivatives maintaining a ring nitrogen as hydrogen bond acceptor (HBA) at the corresponding position. All compounds thus designed displayed strong inhibitory activity against VEGFR2 kinase, and the [1,2,4]triazolo[1,5-a]pyridine 13d displayed favorable physicochemical properties. Furthermore, 13d inhibited VEGFR2 kinase with slow dissociation kinetics and also inhibited platelet-derived growth factor receptor (PDGFR) kinases. Oral administration of 13d showed potent anti-tumor efficacy in DU145 and A549 xenograft models in nude mice.

PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n = 0 or 1 and R2 is a methyl group when n = 0 and a hydrogen atom when n = 1. Process for the preparation thereof and therapeutic use thereof.

THIAZOLE DERIVATIVE

Provided is a compound having an agonist action on GPR52, which is useful as a prophylactic or therapeutic drug for mental diseases such as schizophrenia and the like, and the like. A compound represented by the formula (I): wherein each symbol is as defi